Crossmark

Persistence with topical glaucoma therapy in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data

Crossref DOI link: https://doi.org/10.1186/s12886-025-04474-1

Published Online: 2025-11-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kabeya, Kenji

Satoh, Hiroki

Yanagi, Natsuyo

Sawada, Yasufumi
License Information

Text and Data Mining valid from 2025-11-28

Version of Record valid from 2025-11-28
More Information

Article History

Received: 16 June 2025

Accepted: 21 October 2025

First Online: 28 November 2025

Declarations

:

: Not applicable, as JMDC Inc. ensured that the data was sufficiently anonymized and formal consent was not considered required for this retrospective study. This study was approved by Research Ethics Committee of the Faculty of Pharmaceutical Sciences of the University of Tokyo (approval number: 6–11), in accordance with the Declaration of Helsinki.

: Not applicable, as JMDC Inc. ensured that the data was sufficiently anonymized.

: HS, NY, and YS were the members of an endowed laboratory funded by companies including Ain Pharmaciez Inc., I & H Co., Ltd., Medical Ikkou Co., Ltd., Toho Holdings Co., Ltd., Tomod’s, and Wakaba Co. until March 2025. The companies were not directly involved in this study.

Document is current

Any future updates will be listed below